TCNNF - TDR Research Rates Trulieve Cannabis A 'Buy' Potential 46% Stock Price Upside | Benzinga
TDR Research has recently initiated coverage of multi-state cannabis company Trulieve (OTC: TCNNF), assigning it a "Buy” rating based on an extensive analysis of the company's financial health and growth potential. The report highlights Trulieve's robust financial metrics and strategic positioning in cannabis markets.
The 2024 financial estimates include $1.20 billion in revenue, a 55.1% gross margin and a 24.9% EBITDA margin, projecting an EBITDA of $298.8 million.
Investment Rating
The valuation employs three key methods: Discounted Cash Flow (DCF) growth, DCF revenue, and EV/Revenue. The blended fair value of Trulieve’s stocks is estimated to be $15.29, suggesting a potential upside of 46% from the current price of $10.45. Trulieve’s financial metrics, such as a high current ratio and a lower liabilities-to-assets ratio underpin this potential return.
Strengths
Trulieve Cannabis Corp., a prominent multi-state cannabis retailer, is ...